X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALKEM LABORATORIES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALKEM LABORATORIES AUROBINDO PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 14.3 - - View Chart
P/BV x 2.9 6.0 47.7% View Chart
Dividend Yield % 0.4 0.7 60.5%  

Financials

 AUROBINDO PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ALKEM LABORATORIES
Mar-16
AUROBINDO PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8091,589 50.9%   
Low Rs5041,232 40.9%   
Sales per share (Unadj.) Rs281.1417.5 67.3%  
Earnings per share (Unadj.) Rs41.456.3 73.5%  
Cash flow per share (Unadj.) Rs50.964.7 78.6%  
Dividends per share (Unadj.) Rs2.5012.70 19.7%  
Dividend yield (eoy) %0.40.9 42.3%  
Book value per share (Unadj.) Rs199.4292.9 68.1%  
Shares outstanding (eoy) m585.88119.57 490.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.4 69.1%   
Avg P/E ratio x15.925.1 63.4%  
P/CF ratio (eoy) x12.921.8 59.2%  
Price / Book Value ratio x3.34.8 68.4%  
Dividend payout %6.022.6 26.8%   
Avg Mkt Cap Rs m384,630168,653 228.1%   
No. of employees `00017.3NA-   
Total wages/salary Rs m21,3089,171 232.3%   
Avg. sales/employee Rs Th9,500.7NM-  
Avg. wages/employee Rs Th1,229.4NM-  
Avg. net profit/employee Rs Th1,397.9NM-  
INCOME DATA
Net Sales Rs m164,66649,915 329.9%  
Other income Rs m1,0201,645 62.0%   
Total revenues Rs m165,68651,561 321.3%   
Gross profit Rs m37,7188,482 444.7%  
Depreciation Rs m5,5801,006 554.8%   
Interest Rs m777671 115.9%   
Profit before tax Rs m32,3808,451 383.2%   
Minority Interest Rs m31-114 -27.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,606 509.5%   
Profit after tax Rs m24,2296,731 360.0%  
Gross profit margin %22.917.0 134.8%  
Effective tax rate %25.319.0 133.0%   
Net profit margin %14.713.5 109.1%  
BALANCE SHEET DATA
Current assets Rs m121,87827,062 450.4%   
Current liabilities Rs m86,80615,324 566.5%   
Net working cap to sales %21.323.5 90.6%  
Current ratio x1.41.8 79.5%  
Inventory Days Days13067 195.3%  
Debtors Days Days6841 165.6%  
Net fixed assets Rs m81,03712,610 642.7%   
Share capital Rs m586239 245.0%   
"Free" reserves Rs m116,21834,490 337.0%   
Net worth Rs m116,80435,027 333.5%   
Long term debt Rs m4,5121,212 372.4%   
Total assets Rs m211,05254,387 388.1%  
Interest coverage x42.713.6 313.6%   
Debt to equity ratio x00 111.7%  
Sales to assets ratio x0.80.9 85.0%   
Return on assets %11.813.6 87.1%  
Return on equity %20.719.2 107.9%  
Return on capital %27.424.9 110.1%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m80,7276,563 1,230.0%   
Fx outflow Rs m34,7003,012 1,152.2%   
Net fx Rs m46,0273,552 1,295.9%   
CASH FLOW
From Operations Rs m19,5487,259 269.3%  
From Investments Rs m-19,5701,864 -1,049.8%  
From Financial Activity Rs m8,642-9,273 -93.2%  
Net Cashflow Rs m8,922-150 -5,948.1%  

Share Holding

Indian Promoters % 54.1 66.9 80.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 33.1 24.0%  
FIIs % 27.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 0.0 -  
Shareholders   69,601 68,381 101.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 160 Points Higher; IT and Healthcare Stocks Witness Buying(Closing)

Indian share markets traded on a positive note most of the day and ended higher. Gains were largely seen in the IT sector and healthcare sector, while capital goods stocks witnessed selling pressure.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

This Smallcap Stock could be the next Page Industries(Profit Hunter)

Jul 2, 2019

The smallcap rebound is taking longer to play out...and that's good news as it gives you more of action time and opportunities to invest in.

The Indian Rating Agency Cleanup Has Begun and this Cheap Stock Could be the Best Bet(The 5 Minute Wrapup)

Jul 2, 2019

The last time this big rating agency was as cheap and out-of-favour as it is today, the stock had corrected by 40% in six months.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 15, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ABBOTT INDIA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS